Onconova (NASDAQ: ONTX) was downgraded by Zacks from a “purchase” rating to a “hold” rating in a research note released to capitalists on Thursday, Zacks.com records.
According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It concentrates on finding and also creating small molecule drug candidates to deal with cancer cells. The Firm‘s products under various phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “
Numerous other equities research experts likewise recently discussed the firm. Noble Financial reissued a “acquire” ranking and released a $11.00 cost goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and established a “purchase” ranking on the stock in a research note on Tuesday, September 28th.
NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day moving typical cost of $2.90 and also a two-hundred day relocating typical price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 as well as a beta of 1.67.
Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly profits outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) profits per share for the quarter, topping experts’ consensus price quotes of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and also an adverse internet margin of 8,294.27%. The company had profits of $0.06 million throughout the quarter, contrasted to the agreement quote of $0.06 million. Throughout the exact same quarter in the prior year, the company uploaded ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the existing year.
A variety of hedge funds have actually lately bought and sold shares of ONTX. GSA Resources Partners LLP bought a brand-new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Capital Management LP purchased a brand-new placement in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC bought a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Finally, Dimensional Fund Advisors LP got a brand-new setting in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional investors possess 13.36% of the business’s stock.
Regarding Onconova Therapeutics
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which participates in the identification and also development of oncology therapeutics. It concentrates on uncovering as well as creating small particle medicine prospects to deal with cancer cells. The firm was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA
. Get a free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).
To learn more about research offerings from Zacks Investment Research, visit Zacks.com.
This immediate information alert was created by narrative scientific research technology and financial data from Market in order to give readers with the fastest and most accurate reporting. This tale was evaluated by Market’s editorial group before magazine.
SHOULD YOU SPEND $1,000 IN ONCONOVA THERAPEUTICS TODAY?
Before you consider Onconova Therapeutics, you’ll intend to hear this.
Market keeps an eye on Wall Street’s premier and finest carrying out research analysts as well as the stocks they advise to their customers on a daily basis. Market has actually identified the 5 stocks that top experts are quietly whispering to their customers to purchase currently before the broader market catches on … as well as Onconova Therapeutics wasn’t on the checklist.
While Onconova Therapeutics presently has a “Buy” score amongst experts, premier experts believe these 5 stocks are much better acquires.
